10-Q · May 13, 2026
In its Q1 2026 10-Q filing, Milestone Pharmaceuticals reported revenues of $0.2 million from CARDAMYST's launch, a significant shift from zero revenues in Q1 2025. However, the company recorded a net loss of $26.1…
Earnings analysis · 10-Q
MIST earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt does not contain the current-quarter income statement, cash-flow statement, balance-sheet detail, segment results, or quantitative outlook, so revenue, margins, EPS, free cash flow, and…
Read full summary
The provided 10-Q excerpt does not contain the current-quarter income statement, cash-flow statement, balance-sheet detail, segment results, or quantitative outlook, so revenue, margins, EPS, free cash flow, and year-over-year trends cannot be assessed from the available text. Disclosed liquidity totaled $170.6 million as of June 30, 2026, while management characterized interest-rate sensitivity as limited. Risk factors were unchanged from the March 20, 2026 Form 10-K, but the company disclosed $2.2 million of unhedged Canadian-dollar exposure and termination of the CEO’s trading plan after 80,000 shares were sold.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
$170.6M of disclosed liquidity
As of June 30, 2026, the company reported $169.7 million of cash and cash equivalents plus $0.9 million of short-term investments, or $170.6 million in total disclosed liquidity.
-
Limited short-term rate sensitivity
Management stated that an immediate 10% increase or decrease in interest rates would not materially affect the fair value of the short-term investment portfolio, operating results, or cash flows.
-
Controls remained effective
Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026, and reported no changes in internal control that materially affected or were reasonably likely to materially affect reporting.
-
CEO trading plan terminated
The CEO’s Rule 10b5-1 plan was terminated on June 18, 2026, after 80,000 shares had been sold; the plan had allowed potential sales of up to 2,128,588 shares.
What to watch
-
Unhedged Canadian-dollar exposure
The company had $2.2 million of net monetary exposure denominated in Canadian dollars as of June 30, 2026, and does not use derivative instruments or maintain a formal foreign-exchange hedging program.
-
Potential equity-sale overhang
The terminated CEO trading plan had provided for potential sales of up to 2,128,588 common shares, compared with 80,000 shares sold before termination, creating a disclosed potential equity-sale overhang even though the plan is no longer active.
-
No material risk-factor updates
The company stated that there were no material changes to the risk factors disclosed in its March 20, 2026 Form 10-K; therefore, no new material risk-factor changes were identified in the filing.
Management's outlook
The provided 10-Q excerpt does not include quantitative revenue or EPS guidance, outlook, or liquidity-outlook targets.
Earlier filings 4
10-K · March 20, 2026
Milestone received FDA approval for CARDAMYST (etripamil) on December 12, 2025 and began commercial availability in retail pharmacies in Q1 2026; the company is now focused on commercialization (sales force ~60 reps)…
10-Q · November 12, 2025
Milestone reported no revenue for the quarter and a net loss per share of $(0.12) for the three months ended September 30, 2025, modestly improved from $(0.14) in the prior-year quarter, while loss from operations…
10-Q · May 14, 2025
Milestone reported no revenue for Q1 2025 and a wider net loss of $20,761 (vs $10,354 in Q1 2024), driving diluted loss per share to $(0.31) (vs $(0.21) a year ago). Cash and short-term investments total $56.0 million…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.